FDA Communications Key To Court Dismissal Of Diabetes Product Liability Suits
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck, AstraZeneca and Novo Nordisk's incretin mimetics win as district judge cites FDA’s history of rejecting pancreatic cancer warnings.
You may also be interested in...
FDA Label Decisions On Paxil Don't Deter Verdict Against GSK In Suicide Case
Chicago jury finds GSK failed to adequately warn about risk of suicidal behavior in patients over age 24 taking paroxetine; GSK argued that FDA had found no increased risk in this population.
FDA Label Decisions On Paxil Don't Deter Verdict Against GSK In Suicide Case
Chicago jury finds GSK failed to adequately warn about risk of suicidal behavior in patients over age 24 taking paroxetine; GSK argued that FDA had found no increased risk in this population.
Product Liability Hot Seat: Incretin Mimetics Follow Actos In Racking Up Claims
More than 3,000 plaintiffs claim Takeda’s diabetes drug Actos caused bladder cancer, while more than 50 cases have been brought alleging Januvia, Janument, Victoza and Byetta caused pancreatic cancer.